Quell Therapeutics

Quell Therapeutics is a London-based, privately held biopharmaceutical company dedicated to developing engineered Treg cell therapies. Their vision is to become the leading engineered cell therapy company, bringing transformative treatments for autoimmune and inflammatory diseases, as well as preventing organ rejection in transplantation. Their approach involves harnessing and optimizing the immune-suppressing properties of regulatory T cells (Tregs) through a unique, multi-modular platform. This platform utilizes cutting-edge technologies like the "Foxp3 Phenotype Lock" and CAR engineering to enhance the persistence, potency, and stability of Treg therapies.

Quell's lead candidate, QEL-001, is designed to induce operational tolerance after liver transplantation, potentially eliminating the need for lifelong immunosuppressive medications. They are also advancing programs in neuro-inflammation and autoimmune diseases, both internally and through collaborations, like their partnership with AstraZeneca. Quell's focus on research and development has led to numerous publications in leading scientific journals and presentations at major conferences in the cell therapy and immunology fields.

Quell Therapeutics offers a flexible and dynamic working environment that fosters creativity, leadership, and teamwork. This dynamic work environment means that employees are able to work in a way that suits them best, and are given the freedom to be creative and innovative.

Quell Therapeutics offers a comprehensive benefits package to its employees, including a competitive salary and performance-related bonuses, an employee incentive scheme, a group pension plan, life assurance, and private medical insurance. These benefits reflect their commitment to providing a rewarding and supportive work environment that prioritizes the well-being of their team.

Quell Therapeutics is a London-based private biopharmaceutical company focused on developing engineered cell therapies that leverage the power of regulatory T cells (Tregs) to address a range of autoimmune and inflammatory diseases, as well as preventing organ rejection in transplantation. The company's vision is to become the leading engineered cell therapy company, bringing transformational and valued therapies to patients with a goal of achieving durable immune tolerance and eliminating the need for chronic immunosuppression.

Quell Therapeutics promotes a culture that is deeply rooted in its values: innovation, collaboration, respect, accountability, and integrity. They believe that their success depends on the diverse qualities of their employees and strive to create a unique and engaging work environment that fosters creativity, leadership, and teamwork. The company offers flexible and dynamic working conditions and a comprehensive benefits package, demonstrating their commitment to employee well-being.

Quell Therapeutics emphasizes building a culture that values diversity, equity and inclusion, respecting the unique qualities each employee brings. They strive to create an innovative and collaborative work environment where individuals feel respected, accountable, and demonstrate integrity. They are committed to creating an equal opportunity employer with a culturally diverse team.